InterAx Biotech Ltd and Alveus Therapeutics Inc. have now formed a research collaboration and licensing agreement to jointly develop a novel small molecule drug for metabolic disorders, promising to provide sustaining weight reduction as well as demonstrating improved tolerability to the existing standards of obesity therapies. The recent agreement made on January 15, 2026, will see the two companies team up to leverage InterAx’s proprietary discovery tool, Deep Signal™, designed to help discover and develop superior cellular signaling profiles for drugs, in conjunction with Alveus’s advanced R&D capabilities in the field of obesity, diabetes, and cardiometabolic diseases. The financial details of the agreement have not been made public, though the deal does include upfront payments and a series of development and regulatory milestones. “We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, CEO of InterAx, highlighting the complementary strengths of InterAx’s platform and Alveus’s metabolic expertise that make the collaboration well-positioned to deliver meaningful patient outcomes.
Also Read: Freenome and NVIDIA Expand AI-Driven Deep Learning to Transform Personalized Multi-Cancer Detection
“Our Deep Signal™ platform is specifically designed to navigate the complexity of GPCR signaling, and Alveus’s deep metabolic expertise makes them the ideal partner to bring this therapeutic candidate to patients.” “InterAx’s unique platform integrates drug chemistry, protein structure, cellular signaling and therapeutic efficacy – the essential expertise for effectively and efficiently designing highly differentiated candidates. We are excited to apply this unique approach to our joint program efforts,” added Jacob Jeppesen, Chief Scientific Officer and Head of R&D at Alveus, underscoring the scientific synergy of the partnership. The agreement marks a significant step for InterAx, a Swiss biotech redefining drug discovery with its Deep Signal™ platform that deciphers disease mechanisms at the cellular signaling level to deliver optimized GPCR small molecule candidates with higher efficacy and enhanced safety, and expands its metabolic pipeline alongside a clinical-stage partner with complementary R&D capabilities.